RSS Feed
February 16th, 2012 
FAKE NEWS for the Zionist agenda WEDNESDAY, Feb. 15 (HealthDay News) — A new blood-thinning
medication called semuloparin reduces the risk of blood clots in people
undergoing certain cancer treatments, new research shows.
When people with cancer are treated with chemotherapy, they have an
increased risk of developing blood clots (venous thromboembolism). These
clots can be dangerous, and have the potential to cause heart attacks or
strokes.
This new drug reduced the risk of blood clots by 64 percent, according
to the study, which was funded by Sanofi, the drug’s manufacturer. Sanofi
was also responsible for the analysis of the study’s results.
Semuloparin, which is not currently approved by the U.S. Food and Drug
Administration, didn’t appear to increase the risk of excessive bleeding,
which can be a side effect of blood thinners.
“Thromboembolism and the effects are very significant,” said Dr.
Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New
York City. Even if blood clots don’t cause life-threatening complications,
they can cause lifelong problems, such as pain and a decreased ability to
exercise, she explained.
“What’s interesting about this paper is that they’re decreasing the
rate of thromboembolism without increasing bleeding. This needs to be
confirmed in other studies, but this drug may play an important role for
cancer patients in the future,” said Bernik, who was not involved with the
research.
The current study included more than 3,000 people from 47 countries.
All had been diagnosed with cancer, including cancers of the lung,
pancreas, stomach, colon, rectum, bladder or ovary.
The study volunteers were randomly assigned to one of two groups. One
group received treatment with semuloparin, which is a type of heparin,
while they were undergoing chemotherapy. The other group received a
placebo.
The medication or the placebos were given as an injection once a day.
Treatment lasted an average of 3.5 months.
Blood clots occurred in just 1.2 percent of those taking semuloparin
compared to 3.4 percent of those on the placebo, according to the study.
The incidence of any type of excessive bleeding was 2.8 percent for the
semuloparin group and 2.0 percent in those on placebo. Major bleeding
occurred in 1.2 percent of those on semuloparin and 1.1 percent of those
on placebo.
Results of the study are published in the Feb. 16 issue of the New
England Journal of Medicine.
In addition to preventing clots, heparin medications may also help
fight cancer tumors, according to the authors of an accompanying editorial
in the same issue of the journal.
“This study by itself did not show any effect on mortality, but when we
included it in a meta-analysis, we found that there is a likely
survival benefit,” said one of the editorial’s authors, Dr. Elie Akl, an
associate professor of medicine at the State University of New York at
Buffalo.
The meta-analysis done by Akl and his co-author reviewed 11 studies
including more than 6,000 people taking heparin medications during
chemotherapy. They concluded that for every 1,000 people being treated
with chemotherapy for cancer, there would be 30 fewer deaths if people
were also treated with heparin during their chemotherapy. They also
estimated that there would be 20 fewer blood clots. And, they estimated
that there would be one more major bleeding episode and five more minor
bleeding episodes if everyone on chemotherapy were to receive heparin
treatment.
“Patients with cancer, who have a low risk of bleeding and who have no
problem with injecting themselves with heparin, are likely to benefit in
terms of survival from heparin treatment,” he said.
What isn’t yet clear, Akl said, is if heparin would provide more or
less benefit depending on the type of cancer someone has, and how far
advanced the cancer is. He said that there are currently six different
studies under way to help answer those questions. The cost of the
medication is also unclear, since it has not been approved for use in the
United States yet.
More information
To learn more about blood clots and cancer, read this information from
the American Society of Clinical Oncology.
Related posts:
Views: 0
Posted in 
Tags: 
